{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/macular-degeneration-age-related/background-information/prognosis/","result":{"pageContext":{"chapter":{"id":"c49a0066-054e-5666-9b2d-7bad39b079cc","slug":"prognosis","fullItemName":"Prognosis","depth":2,"htmlHeader":"<!-- begin field 8c08c0dc-37ab-4177-9a0a-5d56966a483b --><h2>What is the prognosis?</h2><!-- end field 8c08c0dc-37ab-4177-9a0a-5d56966a483b -->","summary":"","htmlStringContent":"<!-- begin item 4583afca-201c-4835-97b8-1f5c06412dd6 --><!-- begin field bb857433-a728-4b29-9986-a15288bb187e --><ul><li><strong>Central visual loss is common, but total visual loss is extremely rare in people with age-related macular degeneration (AMD).</strong></li><li><strong>Generally, early and intermediate AMD is not associated with disturbances of central visual function </strong>— when vision loss occurs it is usually due to the development of advanced AMD.</li><li><strong>For people with early AMD, </strong>there is a low risk of progression (1.3%) to advanced AMD after 5 years in either eye. <ul><li>In a 10-year follow-up study of people with small drusen or no drusen at baseline, approximately 15% developed large drusen at 10 years.</li></ul></li><li><strong>For people with intermediate AMD</strong> the risk of progression to advanced AMD after 5 years is approximately 18%. <ul><li>For people with large drusen in one eye, the rate of development to advanced AMD is 6.3% at 5 years and 26% for people with multiple bilateral large drusen. </li><li>In a 10-year follow-up study of people with medium drusen present in one eye at baseline, 37% developed large drusen compared with 71% for people with medium drusen in both eyes.</li><li>When medium drusen are present at baseline, progression to advanced AMD is 14% at 10 years.</li></ul></li><li><strong>For people with advanced AMD </strong>the risk of developing advanced AMD in the other eye ranges from 22–50% at 5 years. <ul><li>Geographic atrophy usually results in less severe visual impairment than neovascular AMD and it occurs more slowly.<ul><li>Doubling of the visual angle (loss of three or more lines on a visual acuity chart) has been reported to occur in up to 50% of people with geographic atrophy over a 2-year period. </li><li>A longitudinal study of geographic atrophy found that three lines of visual acuity are lost in about 31% of people within 2 years of diagnosis, and in about 53% of people within 4 years. </li></ul></li><li>Neovascular AMD, left untreated, progresses to moderate or severe visual loss that can be rapid, within weeks or months. <br><ul><li>A meta-analysis of interventional studies found that in people with untreated neovascular AMD the mean visual acuity change progressed from one line lost at 3 months to around three lines after 12 months and four lines lost after 24 months.</li><li>The risk of neovascular AMD developing in the second eye is 12% at 1 year and 27% at 4 years.</li></ul></li></ul></li><li><strong>For people who receive timely treatment for neovascular AMD,</strong> the prognosis has greatly improved in recent years. <br><ul><li>With treatment, about a third of people will gain some improvement in vision. The majority will maintain vision at their current level, but about 10% will not respond to therapy. <ul><li>Anti-angiogenic drugs could theoretically reduce the rate of legal blindness by up to 70% over 2 years, however, long-term follow-up over 7 years showed these gains in visual acuity were lost in two-thirds of people. </li><li>Factors that affect the effectiveness of anti-angiogenic therapy include visual acuity and lesion size at diagnosis, and the number of injections received.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">Wong, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">Bloch, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">Royal College of Ophthalmologists, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">Schmidt-Erfurth, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">AAO, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">Gill, 2020</a>]</p><!-- end field bb857433-a728-4b29-9986-a15288bb187e --><!-- end item 4583afca-201c-4835-97b8-1f5c06412dd6 -->","topic":{"id":"bb3e11cb-517f-5331-9de9-039d796fed2d","topicId":"819a45d3-fd1c-42c7-8420-27d4daf53cc2","topicName":"Macular degeneration - age-related","slug":"macular-degeneration-age-related","lastRevised":"Last revised in October 2020","chapters":[{"id":"8dda5709-9896-57f9-9907-7fb9c46fe863","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bb451071-7381-59cb-aa21-2b2bccafe2d2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"5006d91f-871e-5987-a351-38613676d868","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b46dda65-9a23-5d6c-9afe-03e05a87cc3c","slug":"changes","fullItemName":"Changes"},{"id":"a82ab674-261f-5a3d-8d12-5c13643cd924","slug":"update","fullItemName":"Update"}]},{"id":"e40fe343-86d1-5303-af86-c3b22d664113","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"807a5294-312b-51b7-8a2b-2b7d9c18a2a2","slug":"goals","fullItemName":"Goals"},{"id":"875cd1b7-ea38-5e4d-b1ac-1c4d4e110927","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1c4bcbde-43f9-57c5-87d2-37e2a7bfc7b3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"73e19abc-9ba2-505a-aae8-23b40e76c49f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cb9a7aab-681a-5b78-aca6-dcb97a9ae535","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"25a06a16-e897-5cb6-bdf2-99705c2c3f77","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7cb3e392-3b5c-558a-988c-646bacf307bb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"69a4bcc6-b18d-52c2-b7f8-b74b4bebf32c","slug":"definition","fullItemName":"Definition"},{"id":"e34a411a-f7c0-5084-965b-49ac89736d30","slug":"classification","fullItemName":"Classification"},{"id":"d537f969-c989-57cd-824a-d0718c657988","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4098eb73-c982-50a6-830c-61d7dc25c997","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c49a0066-054e-5666-9b2d-7bad39b079cc","slug":"prognosis","fullItemName":"Prognosis"},{"id":"1313d171-0d54-5814-baef-2c79e54a147e","slug":"complications","fullItemName":"Complications"}]},{"id":"5daaa827-5772-5a33-8675-cf20b916db2e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7fd2b2d6-9e86-5014-bc61-f30ce19d5712","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"fa4cdf98-731f-5fab-b1b9-802d0ad26a9e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"491fb145-6067-5e5d-b364-2a3d874dcbde","fullItemName":"Management","slug":"management","subChapters":[{"id":"623a85d0-3eef-5b46-a5a6-0c14facafc46","slug":"suspected-amd","fullItemName":"Scenario: Suspected AMD"},{"id":"1d91de12-c8ef-5335-9359-81816456fb81","slug":"confirmed-amd","fullItemName":"Scenario: Confirmed AMD"}]},{"id":"0c6673ad-62d1-59a7-93a7-dc791491644d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"81330a87-dcef-52cd-9707-efa0e22c0435","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"565ac27d-4e4d-5f6c-ba0a-bef0793f4f68","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"97a694f8-29e3-5e9b-9e46-68e52e2499d0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"adea819b-f313-5842-8936-3b1d2feee7ad","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e49d7e10-0bcd-5d89-b7f3-64d4ff858f1c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8059070a-a973-530d-8d9b-0e4cb14d5b65","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4ea345d9-fe7e-558f-b710-2bb252185ef8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7cb3e392-3b5c-558a-988c-646bacf307bb","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}